Economic assessment of the high-tech and primary health care technologies for coronary heart disease according to personalized accounting of medical care for compulsory health insurance
- Authors: Nazarov A.M.1, Saifutdinov R.I.1, Sayfutdinov F.R.1
-
Affiliations:
- Orenburg State Medical University
- Issue: Vol 103, No 5 (2022)
- Pages: 807-814
- Section: Social hygiene and healthcare management
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/97068
- DOI: https://doi.org/10.17816/KMJ2022-807
- ID: 97068
Cite item
Open Access
Access granted
Abstract
Background. The assessment of medical technologies based on digital information is prompt and accurate, but it is currently not widely used, and analysis methods for this have not been developed, which became the basis for this study.
Aim. To economically evaluate the technologies of reperfusion therapy and dispensary observation in coronary heart disease using electronic data on medical care.
Material and methods. 586 patients with myocardial infarction treated in 2016 in two vascular centers of the Orenburg region were identified according to the registers-accounts of the compulsory health insurance fund. Among them were 349 patients with reperfusion therapy (main group) and 237 without it (control group). In the groups, the cost-effectiveness indicator, the cost of inpatient treatment of myocardial infarction and treatment in the postinfarction period were determined. Also, according to the registers-accounts for 2016, 17 225 patients with angina pectoris were identified. Among them, 13 208 patients, who applied to polyclinics for dispensary purposes during 2016–2017, and 4017 patients who did not apply, were registered — the main and control groups. Between groups, the total cost of outpatient, emergency, emergency hospital care and the cost-effectiveness ratio were compared. When processing the data, linear statistics methods and parametric comparison methods (Student's t-test and z-test) were used.
Results. The cost-effectiveness indicator in the group with reperfusion therapy was 425 879, without it — 643 069 rubles/unit, 1.5 times more in the control group. In the postinfarction period, the cost of treatment in the main group was lower than in the control group, 1223.66±19.04 and 1321.11±21.15 rubles, respectively, for outpatient care (p=0.001), 35 138.9±1299.85 and 51 189.6±4903.15 rubles for inpatient care (p=0.002), 4093.0±58.98 and 5428.6±52.95 rubles for an ambulance (p=0.001). The cost of angina treatment in the main group was 2.1 times less than in the control group, 6541.3±85.58 and 13 671.4±92.12 rubles (p=0.001). The cost-effectiveness indicator in the main group was 6867, in the control group it was 15 293 rubles/unit, 2.2 times more in the control group.
Conclusion. The use of reperfusion therapy and dispensary observation in coronary heart disease is economically feasible.
Full Text
About the authors
Alexander M. Nazarov
Orenburg State Medical University
Author for correspondence.
Email: a.m.nazarow@yandex.ru
ORCID iD: 0000-0003-4975-9336
M.D., Cand. Sci. (Med.), Assoc. Prof., Depart. of Anesthesiology and Intensive Care
Russian Federation, Orenburg, RussiaRustam I. Saifutdinov
Orenburg State Medical University
Email: uralcard@esoo.ru
ORCID iD: 0000-0001-6504-8900
M.D., D. Sci. (Med.), Prof., Head, Depart. of Faculty Therapy and Endocrinrology
Russian Federation, Orenburg, RussiaFarkhad R. Sayfutdinov
Orenburg State Medical University
Email: farhad.sajfutdinov@yandex.ru
ORCID iD: 0000-0002-6257-6529
M.D.
Russian Federation, Orenburg, RussiaReferences
- Chazova IE, Oschepkova EV. The fight against cardiovascular diseases: problems and solutions at the present stage. Vestnik Roszdravnadzora. 2015;(5):7–10. (In Russ.)
- Data on mortality by causes of death in the Russian Federation for January-December 2017. Federal State Statistics Service. https://www.gks.ru/free_doc/2017/demo/t3_3.xls (access date: 01.07.2021). (In Russ.)
- Benjamin E, Virani S, Callaway C, Chiuve SE, Cushman M. Heart Disease and Stroke Statistics — 2018 Update: A Report From the American Heart Association. Circulation. 2018;137:e67–e492. doi: 10.1161/CIR.0000000000000558.
- Kontsevaya AV, Kalinina AM, Koltunov IE, Oganov RG. Socio-economic damage by acute coronary syndrome in Russian Federation. Rational Pharmacotherapy in Cardiology. 2011;7(2):158–166. (In Russ.) doi: 10.20996/1819-6446-2011-7-2-158-166.
- Loewen L, Roudsari A. Evidence for business intelligence in health care: a literature review. Stud Health Technol Inform. 2017;235:579–583.
- IT glossary: big data. Stamford, CT: Gartner; 2012. http://www.gartner.com/it-glossary/big-data/ (access date: 17.06.2014).
- White S. A review of big data in health care: challenges and opportunities. Open Access Bioinformatics. 2014;6:13–18. doi: 10.2147/OAB.S50519.
- Hintz JE, O’Connor MC. First steps in the era of value-based health care purchasing. Western Springs: National Law Review; 2012. http://www.natlawreview.com/article/first-steps-era-value-based-health-care-purchasing (access date: 18.06.2014).
- Karachevtseva MA, Mikhaylov SM, Chavpetsov VF. Logika i metodologiya ekspertizy kachestva lechebno-diagnosticheskogo protsessa v otdel′nom sluchaye okazaniya pomoshchi. Uchebnoye posobiye. (Logic and methodology of examination of the quality of the treatment and diagnostic process in a particular case of assistance. Tutorial.) M.-SPb.: SPbGMA im. I.I. Mechnikova; 2008. 51 р. (In Russ.)
- Guidelines “Procedure for the development and application of Protocols for the management of patients”. Approved March 3, 2006. Ministry of Health and Social Development of the Russian Federation. https://cyberleninka.ru/article/n/metodicheskie-rekomendatsii-poryadok-razrabotki-i-primeneniya-protokolov-vedeniya-bolnyh (access date: 23.01.2022). (In Russ.)
- Ryzhakov AD, Bereznikov AV, Lebedeva AM, Promin ME, Onufriychuk YO. Medical care quality: principles of interaction between healthcare organizations and health insurance companies. Vestnik Roszdravnadzora. 2014;(4):30–35. (In Russ.)
- GOST R 56044-2014. Otsenka meditsinskikh tekhnologiy. (Assessment of medical technologies.) M.: Standartinform; 2014. 45 р. (In Russ.)
- Metodicheskiye rekomendatsii po ispol'zovaniyu pokazatelya “Poteryannyye gody potentsial'noy zhizni” (PGPZH) dlya obosnovaniya prioritetnykh problem zdorov'ya naseleniya Rossii na federal'nom, regional'nom i munitsipal'nom urovnyakh. (Methodological recommendations on the use of the Years of Potential Life Lost (YPLL) indicator to substantiate the priority health problems of the Russian population at the federal, regional and municipal levels.) M.: TSNIM OIZ; 2014. 32 р. (In Russ.)
- Yagudina RI, Kulikov AYu, Nguyen T. Place of threshold willingness-to-pay of Russia among those of other european countries and cis countries. Farmakoekonomika. 2011;4(1):129. (In Russ.)
- Gubler EV. Vychislitel'nye metody analiza i raspoznavaniya patologicheskikh protsessov. (Computational methods for the analysis and recognition of pathological processes.) Leningrad: Meditsina; 1978. 288 р. (In Russ.)
- Borovikov VP. STATISTICA. Iskusstvo analiza dannykh na komp'yutere: dlya professionalov. (STATISTICS. The art of computer data analysis: for professionals.) Saint-Petersburg: Piter; 2003. 688 р. (In Russ.)
Supplementary files
